India faces a profound challenge in managing rare diseases, conditions that collectively affect an estimated 96 million people—roughly 6-8% of the population. A groundbreaking study published in PLOS Global Public Health has illuminated a critical bottleneck: the glaring lack of knowledge and training among general doctors, who serve as the first point of contact for most patients. This revelation underscores the urgent need for reforms in medical education to equip future physicians with the skills to recognize, diagnose, and refer rare disease cases effectively.

The study, titled "Mapping the rare disease stakeholders in India," conducted semi-structured interviews with 33 representatives from 10 key stakeholder groups, including general practitioners, specialists, patient organizations, and policymakers. It paints a picture of an ecosystem where high-powered players like government bodies and multinational companies hold sway, but frontline healthcare workers lag far behind in awareness and engagement. With rare diseases often presenting nonspecific symptoms mimicking common ailments, this knowledge gap leads to diagnostic odysseys lasting 5-7 years on average, exacerbating patient suffering and straining specialized resources.

🩺 Unpacking the PLOS Study: Methodology and Core Insights

Researchers from the Indian Institute of Science, Institute of Public Health Bengaluru, and Sree Chitra Institute for Medical Sciences systematically mapped India's rare disease landscape. Using an adapted stakeholder analysis framework, they scored groups on knowledge, interest, position, and power on a 0-3 scale. Principal component analysis revealed two axes: engagement (knowledge + interest + position) and influence (power). General doctors, termed non-rare disease specialists (NRDS), scored a dismal 1.75 in knowledge—described as "limited/general"—with many admitting they "have not encountered an RD patient and are not aware of various diagnostic possibilities."

Allied health professionals (AHPR), such as physiotherapists and genetic counselors, fared slightly better at 2.4 but showed wide intra-group variation and gaps in clinical screening skills. In contrast, rare disease specialists (RDS) and policymakers scored near-perfect 3.0s. Low engagement among NRDS (interest score: 0.5) burdens the few RDS concentrated in urban centers like Delhi and Mumbai, creating inequities in rural access.

This disparity highlights how medical training must evolve. India's 700+ medical colleges graduate over 100,000 MBBS doctors annually, yet rare diseases—over 7,000 identified globally, with 213 officially registered here—receive scant attention in curricula dominated by high-burden conditions like diabetes and tuberculosis.

India's Rare Disease Burden: Statistics and Real-World Impact

Rare diseases are chronic, often genetic, and life-threatening, affecting fewer than 1 in 2,500 individuals per condition but totaling massive numbers collectively. In India, prevalence estimates range from 1:5,000 to 1:10,000, translating to 70-96 million patients. Genetic forms dominate (80%), with challenges amplified by consanguineous marriages in certain communities. Common examples include hemophilia, muscular dystrophy, and Gaucher disease, many treatable if diagnosed early via newborn screening or genetic testing.

Yet, misdiagnosis is rampant. General doctors, handling 80% of primary care via Ayushman Bharat Health and Wellness Centres, often dismiss symptoms as psychosomatic or infectious. A patient with Pompe disease might be labeled asthmatic for years. Diagnostic delays cost lives and livelihoods; enzyme replacement therapies for lysosomal storage disorders can exceed ₹50 lakh annually, unaffordable without policy support.

Stakeholder Ecosystem: Power Dynamics and Engagement Gaps

The study delineates 10 groups:

• Patient Organizations (PATO): High engagement (knowledge 2.6), vocal advocates but low power.
• Rare Disease Specialists (RDS): Technical experts (knowledge/power 3.0/2.0), overwhelmed.
• General Doctors (NRDS): Low across board (knowledge 1.75, interest 0.5, power 1.0).
• Allied Health Pros (AHPR): Variable, genetic counselors shine.
• Policymakers (PMKR): Dominant influence (power 2.4).
• Multinational Companies (MNCO), Think Tanks (TTNK), Research Communities (RCOM), International Orgs (INTO), Orphan Med Product Orgs (OMPO).

High-influence quadrants hold PMKR, MNCO, RDS; low-influence, high-engagement includes PATO and INTO. Bridging this requires empowering grassroots players through university-led training hubs.

Photo by Bloom IVF Centre Lucknow on Unsplash

Medical Education's Role: Deficiencies in MBBS and Beyond

India's medical education, regulated by the National Medical Commission (NMC), emphasizes competency-based curricula since 2019. Yet, rare diseases occupy minimal space—perhaps a lecture in community medicine. MBBS students, trained in 5.5 years across 612 colleges (2026 data), focus on common pathologies. Postgraduate MD/MS programs offer genetics electives, but only 12 NIRF-ranked medical universities like AIIMS prioritize rare diseases via Centers of Excellence (CoEs).

The PLOS study urges "specialty courses or training for health professionals." Universities like PGIMER Chandigarh and Sanjay Gandhi Postgraduate Institute Lucknow lead CoEs, but scaling to general colleges is needed. Competency-Based Medical Education (CBME) could integrate RD modules: symptom checklists, genetic referral protocols, and multidisciplinary case studies.National Policy for Rare Diseases (NPRD) 2021 mandates CoE training, yet implementation lags.

Current Initiatives: Awareness Programs and University Efforts

Progress is emerging. Organization for Rare Diseases India (ORDI) runs webinars and MBBS sensitization. Rare Diseases Action Summit 2026 highlighted training needs. IIT Madras and AIIMS collaborate on genomic diagnostics. Medical colleges like Kasturba Medical College host RD awareness weeks, featuring guest lectures from RDS.

Case study: Christian Medical College Vellore's genetic clinic trains 200+ residents yearly, reducing referral times by 40%. Such models, replicable via NMC guidelines, could embed RD simulations in OSCE exams.

Policy Framework: NPRD 2021 and 2026 Updates

NPRD 2021 prioritizes prevention, diagnosis via CoEs, financial aid (₹50 lakh cap per patient), and research. Budget 2026 added 7 diseases for duty exemptions. Yet, challenges persist: only 12 CoEs operational, training modules absent. Updates call for curriculum integration, echoing PLOS recommendations.Research Matters analysis stresses frontline training.

Universities must align: NMC's proposed RD elective in MBBS phase 3 could standardize knowledge.

Centers of Excellence: University-Led Hubs Driving Change

CoEs like AIIMS Delhi, PGIMER, and NIMHANS Bengaluru offer MD-PhD tracks in genetics, training 500+ specialists yearly. They host CMEs for GPs, with 10,000+ attendees since 2021. Expanding to state universities (e.g., King George's Medical University) via NPRD funding could democratize expertise.

Photo by Cosmetica India Academy on Unsplash

Bridging the Gap: Actionable Recommendations for Higher Education

To address PLOS findings:

• Incorporate RD modules in MBBS (10-15 hours: epidemiology, red flags, ethics).
• Mandate genetic counseling rotations for interns.
• Partner with ORDI for virtual simulations.
• Fund faculty development via ICMR grants.
• Track outcomes via NMC competency logs.

Step-by-step: (1) NMC revises CBME; (2) Colleges pilot modules; (3) Evaluate via pre-post quizzes; (4) Scale nationally.

Global Lessons and Future Outlook

Europe's ERN networks inspire India's RD registry. By 2030, universal MBBS RD training could halve diagnostic delays. With 1.4 billion population, proactive higher ed reforms position India as RD leader.

Stakeholder alliances—universities, PATO, government—will transform challenges into opportunities.